Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: squetch who wrote (1339)	12/3/1997 12:17:00 AM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 4676

Stan: >>With no science degree, are you saying I am better off. I have no burden of old biochemistry knowledge.(:>)<< No! Only I send signal that my writing (based on what I know) may mislead reader and I am suggesting careful evaluation of all aspect in company fundamental. I do not think that yeast is answer. For complex mechanism study, Yes. But this is only one step. >>Jim McCamant has ISIP as a buy up to $20..<< Jim have ruff day today. After being optimistic on AGPH cancer projects (MMP actually didn't change after Thymitaq discontinuation) Roche putted knife in his back. Hope story will not repeat with ISIP. Novartis is on track and BI (with poor pipeline) needs ICAM-1 program. Anyway, to me appears that Big pharma are friendly dividing Health care cake between themselves and we may have some additional structuring on the pharma-bt deals. For instance, Roche do not have strong in-house cancer program and they are simply bailing out. mz